Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has issued an announcement.
QIAGEN has disclosed a managers’ transaction involving Roland Sackers, a member of its managing body, under market abuse regulations. The transaction centers on the release of 4,705 Performance Stock Units granted in 2016 and the net settlement into 2,504 common shares outside a trading venue.
Because a portion of the shares was withheld to cover taxes and related expenses, the transaction is described as not quantifiable in terms of price and volume aggregation. The move reflects routine equity-based compensation practices and provides transparency to investors regarding executive share-based incentives and their eventual conversion into equity.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed on several European exchanges as well as the NYSE and Swiss markets, reflecting a broad international investor base.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.